Monofocal IOL Visual Outcomes When Targeting Mini Monovision

Not Applicable

Completed

• Conditions: Cataract; Presbyopia
• Interventions: Device: Eyhance IOL

• Registration Number: NCT05069415
• Lead Sponsor: Carolina Eyecare Physicians, LLC

Brief Summary

This study is a 3-month, prospective, up to 2 center, bilateral, randomized subject masked clinical evaluation of a monofocal intraocular lens (IOL) when both eyes are targeted for emmetropia and when the non-dominant eye is targeted for mini monovision (-0.75 D) in patients with or without astigmatism undergoing routine cataract surgery.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2021-09-13
• Study Start: 2021-10-04
• Study First Submitted QC: 2021-10-05
• Study First Posted: 2021-10-06
• Primary Completion: 2022-11-30
• Study Completion: 2022-11-30
• Status Verified: 2024-01
• Results First Submitted: 2024-01-19
• Results First Submitted QC: 2024-01-19
• Last Update Submitted: 2024-01-19
• Results First Posted: 2024-02-13
• Last Update Posted: 2024-02-13

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 75

Inclusion Criteria

• Subject is undergoing bilateral cataract extraction with intraocular lens implantation.
• Willing and able to provide written informed consent for participation in the study
• Willing and able to comply with scheduled visits and other study procedures.
• Scheduled to undergo standard cataract surgery in both eyes within 6 - 30 days between surgeries.
• Subjects who require an IOL power in the range of +5.0 D to +34.0 D only.
• Potential postoperative visual acuity of 0.2 logMAR (20/32 Snellen) or better in both eyes.

Read More

Exclusion Criteria

• Severe preoperative ocular pathology: amblyopia, rubella cataract, proliferative diabetic retinopathy, shallow anterior chamber, macular edema, retinal detachment, aniridia or iris atrophy, uveitis, history of iritis, iris neovascularization, medically uncontrolled glaucoma, microphthalmos or macrophthalmos, optic nerve atrophy, macular degeneration (with anticipated best postoperative visual acuity less than 20/30), advanced glaucomatous damage, etc.
• Uncontrolled diabetes.
• Use of any systemic or topical drug known to interfere with visual performance.
• Contact lens use during the active treatment portion of the trial.
• Any concurrent infectious/non-infectious conjunctivitis, keratitis or uveitis.
• Clinically significant corneal dystrophy.
• Irregular astigmatism.
• History of chronic intraocular inflammation.
• History of retinal detachment.
• Pseudoexfoliation syndrome or any other condition that has the potential to weaken the zonules.
• Previous intraocular surgery.
• Previous refractive surgery.
• Previous keratoplasty
• Severe dry eye
• Pupil abnormalities
• Subject who may reasonably be expected to require a secondary surgical intervention at any time during the study (other than YAG capsulotomy, i.e. LASIK)
• Anesthesia other than topical anesthesia (i.e. retrobulbar, general, etc).
• Any clinically significant, serious or severe medical or psychiatric condition that may increase the risk associated with study participation or may interfere with the interpretation of study results.
• Participation in (or current participation) any ophthalmic investigational drug or ophthalmic device trial within the previous 30 days prior to the start date of this trial.

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Emmetropia	Eyhance IOL	The target refraction for both eyes will be emmetropia (± 0.25 D).
Mini monovision	Eyhance IOL	The target refraction for the dominant eye will be plano (± 0.25 D) and for the non-dominant eye between -0.75D ±0.15.

Primary Outcome Measures

Name	Time	Method
Binocular Distance-corrected Intermediate (66 cm) Visual Acuity at 3 Months.	3 months

Secondary Outcome Measures

Name	Time	Method
Binocular Low Contrast Distance Visual Acuity at 3 Months	3 months
Distance-corrected Near Visual Acuity at Best Distance at 3 Months	3 months

Trial Locations

Locations (2)

Carolina Eyecare Physicians, LLC; 🇺🇸 Mount Pleasant, South Carolina, United States

Center for Sight; 🇺🇸 Sarasota, Florida, United States